

Supplementary Table 1. Prevalence of *MET* tyrosine kinase domain (TKD) mutations in each dataset of the cohort #1.

Cohort Tumor types N (unique patients)	Individual cohorts					Total (cohort #1)
	GENIE Pan-cancer (N=81,025)	China Pan- Cancer Pan-cancer (N=10,194)	TCGA Pan-cancer (N=10,953)	DFCI Pan-cancer (N=34,989)	MSKCC NSCLC (N=8,788)	Total Pan-cancer (N=145,949)
<i>MET</i> TKD mutations	300 (0.37%)	40 (0.39%)	64 (0.58%)	233 (0.66%)	55 (0.62%)	692 (0.47%)
<i>MET</i> TKD mutations with concurrent <i>MET</i> exon 14 alterations	8 (0.01%)	0	0	9 (0.02%)	11 (0.12%)	28 (0.01%)
<i>MET</i> TKD without concurrent <i>MET</i> exon 14 alterations	292 (0.36%)	40 (0.39%)	64 (0.58%)	224 (0.64%)	44 (0.5%)	664 (0.45%)